FDA qualifies C-Path’s DIBSS-C for clinical trials

Critical Path Institute's (C-Path) Patient-Reported Outcome (PRO) Consortium announces the qualification of the Diary for Irritable Bowel Syndrome Symptoms-Constipation (DIBSS-C) by the U.S. Food and Drug Administration (FDA).

The DIBSS-C was developed by the PRO Consortium's Irritable Bowel Syndrome (IBS) Working Group to support symptom-based efficacy endpoints in clinical trials for products intended to treat constipation-predominant IBS (IBS-C) in adults. Qualification of the DIBSS-C represents a major milestone for the IBS Working Group and is the PRO Consortium's fourth clinical outcome assessment (COA) to be qualified through the COA Qualification Program within FDA's Center for Drug Evaluation and Research.

"The multi-stakeholder collaboration within the Critical Path Institute's PRO Consortium, inclusive of sponsors, patients, measurement experts and FDA has been critical in enabling the incorporation of the patient's voice in IBS drug development and product labeling.

The availability of the DIBSS-C for use in IBS-C trials is a huge win for patients since it is aimed assessing the impact of treatment on symptoms that matter to them and informing their treatment decision-making for this burdensome condition," stated Robyn T. Carson, MPH, Vice President, Patient-Centered Outcomes Research, at AbbVie and co-chair of the PRO Consortium's IBS Working Group.

IBS is a chronic functional bowel disorder characterized by recurrent episodes of abdominal pain associated with alterations in bowel movements. Diagnosis of functional bowel disorders, like IBS, is based on symptom criteria because there are no consistent and reliable diagnostic biomarkers. Because these symptoms are subject to natural variability, the DIBSS-C was developed as a daily and event-based diary to facilitate the collection of reliable data in clinical trials evaluating treatments for this condition.

The qualification of the DIBSS-C exemplifies FDA's commitment to the needs of the gastrointestinal illness community. It is a clear indication that patient voices are being heard and a huge win for the community as a whole. IFFGD is proud to be a part of the PRO Consortium's IBS Working Group and we are excited to see the continued emphasis on meeting true patient needs by listening to patient voices."

Ceciel T. Rooker, President of International Foundation for Gastrointestinal Disorders and  Participant in IBS Working Group, Critical Path Institute

The DIBSS-C signifies an important advancement in PRO assessment in drug development for IBS-C and reflects FDA's commitment to patient-focused drug development through qualification of COAs that capture valid, reliable, and meaningful data. Stephen Joel Coons, Ph.D., the PRO Consortium's Executive Director, affirmed that, "The qualification of the DIBSS-C is an incredibly gratifying achievement for the PRO Consortium. It is the result of a substantial amount of time and effort invested by C-Path, our industry partners, clinical and measurement consultants, FDA, and the patients who participated in this very worthwhile project. The DIBSS-C has the potential to change the current measurement paradigm for assessing clinical benefit in treatment trials for IBS-C."


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Antibody responses following SARS-CoV-2 infection more potent than vaccine-elicited ones